Aileron Therapeutics ALRN 深 沪
等待开盘 07-24 09:30:00 美东时间
2.11
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.11
- 总市值 4.57万
- 52周最高 7.42
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.61
- 委 比 0.00%
- 总股本 2.17万
- 历史最高 309.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.01
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Kymera Therapeutics appoints Penny Carlson as Senior Vice President, Development Operations, overseeing global clinical development for its oral immunology portfolio. Carlson brings over 20 years of biopharmaceutical leadership experience. Jeremy Chadwick, former Chief Operating Officer, will retire and remain as an advisor until year-end. Kymera is advancing a pipeline of oral small molecule degraders for immunological diseases.
06-08 20:01
Aileron Therapeutics Q2 EPS $(0.28) Misses $(0.22) Estimate
Aileron Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 37.78 percent increase over losses of $(0.45) per share
2025-08-15 04:14
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets C...
2025-01-11 00:30
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to enhance lung function in IPF patients.
2024-11-14 02:04
快讯 | Aileron Therapeutics和Advancium Health Network宣布独家期权协议，收购用于视网膜母细胞瘤的Alrn-6924
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option ...
2024-10-31 19:30
Aileron Therapeutics to Present at the 8th Annual IPF Summit
AUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Ailer...
2024-08-20 04:05
快讯 | Aileron Therapeutics，Inc. Q2营业费用为903.9万美元。
Aileron Therapeutics, Inc. Q2 Operating Expenses USD 9.039 Million
2024-08-15 06:05
